Sec Form 4 Filing - MONTECALVO DAVID A @ WEST PHARMACEUTICAL SERVICES INC - 2020-07-28

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person MONTECALVO DAVID A 2. Issuer Name and Ticker or Trading Symbol WEST PHARMACEUTICAL SERVICES INC [ WST] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP, Glob Ops and Supply Chain (Last) (First) (Middle) 530 HERMAN O. WEST DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 07/28/2020 (Street) EXTON, PA19341 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

07/29/2020 Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/28/2020 M 10,792 A $ 71.79 15,732.42 D Common Stock 07/28/2020 M 3,000 A $ 83.47 18,732.42 D Common Stock 07/28/2020 S 716 D $ 266.058 18,016.42 D Common Stock 07/28/2020 S 7,773 D $ 264.1315 ( 1 ) 10,243.42 D Common Stock 07/28/2020 S 2,881 D $ 265.1292 ( 2 ) 7,362.42 D Common Stock 07/28/2020 S 138 D $ 265.8507 ( 3 ) 7,224.42 D Common Stock 07/28/2020 S 3,000 D $ 265.9769 ( 4 ) 4,224.42 D Common Stock M 5,358 A $ 83.47 9,582.42 D Common Stock 07/29/2020 S 3,273 D $ 270.7038 6,309.42 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 71.79 07/28/2020 M 10,792 02/23/2017 09/26/2026 Common Stock 10,792 $ 0 0 D Stock Options (Right to buy) $ 83.47 07/28/2020 M 3,000 02/21/2018 02/21/2027 Common Stock 3,000 $ 0 8,144 D Stock Options (Right to buy) $ 83.47 07/29/2020 M 5,358 02/21/2018 02/21/2027 Common Stock 5,358 $ 0 2,786 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other MONTECALVO DAVID A 530 HERMAN O. WEST DRIVE EXTON, PA19341 SVP, Glob Ops and Supply Chain Signatures Ryan Metz as Agent for David A. Montecalvo 07/29/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $263.80 to $264.79, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. ( 2 )The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $264.80 to $265.77, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. ( 3 )The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $265.80 to $265.87, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. ( 4 )The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $265.9762 to $265.9769, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.